These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 29086699)

  • 1. Combining in vitro and in silico Approaches to Find New Candidate Drugs Targeting the Pathological Proteins Related to the Alzheimer's Disease.
    Li H; Wang X; Yu H; Zhu J; Jin H; Wang A; Yang Z
    Curr Neuropharmacol; 2018; 16(6):758-768. PubMed ID: 29086699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aβ regulation-based multitarget strategy for drug discovery against Alzheimer's disease.
    Guo X; Jiang W; Li C; Zhu Z; Shen X
    Rev Neurosci; 2015; 26(1):13-30. PubMed ID: 25720054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Key Peptides and Proteins in Alzheimer's Disease.
    Penke B; Bogár F; Paragi G; Gera J; Fülöp L
    Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current thinking on the mechanistic basis of Alzheimer's and implications for drug development.
    Ising C; Stanley M; Holtzman DM
    Clin Pharmacol Ther; 2015 Nov; 98(5):469-71. PubMed ID: 26250900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging drug targets for Aβ and tau in Alzheimer's disease: a systematic review.
    West S; Bhugra P
    Br J Clin Pharmacol; 2015 Aug; 80(2):221-34. PubMed ID: 25753046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening of treatment targets for Alzheimer's disease from the molecular mechanisms of impairment by β-amyloid aggregation and tau hyperphosphorylation.
    Lin LF; Luo HM
    Neurosci Bull; 2011 Feb; 27(1):53-60. PubMed ID: 21270904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.
    Panza F; Solfrizzi V; Frisardi V; Imbimbo BP; Capurso C; D'Introno A; Colacicco AM; Seripa D; Vendemiale G; Capurso A; Pilotto A
    Aging Clin Exp Res; 2009 Dec; 21(6):386-406. PubMed ID: 20154508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease.
    Kalra J; Khan A
    Eur J Pharmacol; 2015 Oct; 764():571-581. PubMed ID: 26209363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer's Disease and other Tauopathies: Exploring Efficacy of Medicinal Plant-derived Compounds in Alleviating Tau-mediated Neurodegeneration.
    Durairajan SSK; Selvarasu K; Bera MR; Rajaram K; Iyaswamy A; Li M
    Curr Mol Pharmacol; 2022; 15(2):361-379. PubMed ID: 34488602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.
    Blennow K; Hampel H; Zetterberg H
    Neuropsychopharmacology; 2014 Jan; 39(1):189-201. PubMed ID: 23799530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in the development of new drugs in Alzheimer's disease.
    Piau A; Nourhashémi F; Hein C; Caillaud C; Vellas B
    J Nutr Health Aging; 2011 Jan; 15(1):45-57. PubMed ID: 21267520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why Is Research on Amyloid-β Failing to Give New Drugs for Alzheimer's Disease?
    Doig AJ; Del Castillo-Frias MP; Berthoumieu O; Tarus B; Nasica-Labouze J; Sterpone F; Nguyen PH; Hooper NM; Faller P; Derreumaux P
    ACS Chem Neurosci; 2017 Jul; 8(7):1435-1437. PubMed ID: 28586203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Abeta and tau in Alzheimer's disease, an early interim report.
    Golde TE; Petrucelli L; Lewis J
    Exp Neurol; 2010 Jun; 223(2):252-66. PubMed ID: 19716367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theranostic F-SLOH mitigates Alzheimer's disease pathology involving TFEB and ameliorates cognitive functions in Alzheimer's disease models.
    Iyaswamy A; Wang X; Krishnamoorthi S; Kaliamoorthy V; Sreenivasmurthy SG; Kumar Durairajan SS; Song JX; Tong BC; Zhu Z; Su CF; Liu J; Cheung KH; Lu JH; Tan JQ; Li HW; Wong MS; Li M
    Redox Biol; 2022 May; 51():102280. PubMed ID: 35286997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Development of SPECT Probes for In Vivo Imaging of β-Amyloid and Tau Aggregates in the Alzheimer's Disease Brain].
    Watanabe H
    Yakugaku Zasshi; 2017; 137(11):1361-1365. PubMed ID: 29093372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should drug discovery scientists still embrace the amyloid hypothesis for Alzheimer's disease or should they be looking elsewhere?
    Imbimbo BP; Ippati S; Watling M
    Expert Opin Drug Discov; 2020 Nov; 15(11):1241-1251. PubMed ID: 32686970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of tau protein in Alzheimer's disease: The prime pathological player.
    Muralidar S; Ambi SV; Sekaran S; Thirumalai D; Palaniappan B
    Int J Biol Macromol; 2020 Nov; 163():1599-1617. PubMed ID: 32784025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction between Aβ and Tau in the Pathogenesis of Alzheimer's Disease.
    Zhang H; Wei W; Zhao M; Ma L; Jiang X; Pei H; Cao Y; Li H
    Int J Biol Sci; 2021; 17(9):2181-2192. PubMed ID: 34239348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural products as a rich source of tau-targeting drugs for Alzheimer's disease.
    Calcul L; Zhang B; Jinwal UK; Dickey CA; Baker BJ
    Future Med Chem; 2012 Sep; 4(13):1751-61. PubMed ID: 22924511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future.
    Hampel H; Schneider LS; Giacobini E; Kivipelto M; Sindi S; Dubois B; Broich K; Nisticò R; Aisen PS; Lista S
    Expert Rev Neurother; 2015 Jan; 15(1):83-105. PubMed ID: 25537424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.